Lithium toxicity profile: a systematic review and meta-analysis.

By Rebecca F. McKnight, M. Adida, Katie Budge, S. Stockton, Guy M. Goodwin, John R. Geddes. The Lancet, 2012

816 citations recorded by the source corpus.

Subfields: Neurology, Psychiatry and Mental health

View Paper: https://www.semanticscholar.org/paper/a0df5519d2a4e66932c004af096f696433b9ae24

How researchers see this paper

The researchers whose trusted networks rank it highest, strongest advocate first. Every researcher gets a different order.

In Neurology

1. Paul B. Fitzgerald
2. Sidney H. Kennedy
3. L. Yatham

In Psychiatry and Mental health

1. Christoph U. Correll
2. L. Yatham

Citations in the corpus

• Canadian Network for Mood and Anxiety Treatments (CANMAT) and International Society for Bipolar Disorders (ISBD) collaborative update of CANMAT guidelines for the management of patients with bipolar disorder: update 2013. (2013, background): “78), as well as increases in thyroid-stimulating hormone and parathyroid hormone (380).”
• Effects of antipsychotics, antidepressants and mood stabilizers on risk for physical diseases in people with schizophrenia, depression and bipolar disorder (2015, background): “17), but effects are generally mild (40).”
• Royal Australian and New Zealand College of Psychiatrists clinical practice guidelines for mood disorders (2015, background): “, 1994) but a recent metaanalysis (McKnight et al., 2012) did not find an increased risk for Epstein’s anomaly and concluded that the evidence that exposure to lithium is teratogenic is quite weak, and findings accord with the notion that the risk has been overestimated.”
• The Lancet Psychiatry Commission: a blueprint for protecting physical health in people with mental illness. (2019, neutral): “266 Lithium is also associated with thyroid disease, 267 including development of goitre (in up to 50% of patients 268 ), hypo thyroidism, 269 or hyper-thyroidism.”
• Evidence-based guidelines for treating bipolar disorder: revised third edition Recommendations from the British Association for Psychopharmacology (2009, neutral): “However, studies have never been large enough (and so included too few cases) to be decisive (McKnight et al., 2012).”